g*e
4 楼
本想抽插一下,想不到成了股东。
话说一切都有可能,下10上20。其实它家的药到现在为止是最好的。只是不能提前上市
“Prosensa and Glaxo started to lose ground against Sarepta in August, after
the two companies released disappointing phase 2 trial results that didn't
measure up to Sarepta's. One particular damaging comparison was in the
production of dystrophin, a protein required for muscle growth that DMD
patients lack. Prosensa's drug showed dystrophin production in 72% of
patients receiving a continuous dose of the drug, whereas Sarepta's drug
resulted in a 100% success rate. ”
话说一切都有可能,下10上20。其实它家的药到现在为止是最好的。只是不能提前上市
“Prosensa and Glaxo started to lose ground against Sarepta in August, after
the two companies released disappointing phase 2 trial results that didn't
measure up to Sarepta's. One particular damaging comparison was in the
production of dystrophin, a protein required for muscle growth that DMD
patients lack. Prosensa's drug showed dystrophin production in 72% of
patients receiving a continuous dose of the drug, whereas Sarepta's drug
resulted in a 100% success rate. ”
l*i
5 楼
不是光不能提前上市的问题。FDA可能对药物的效果有疑问,需要进行三期临床,而且
原来的ENDPOINT可能不能用了,要改用新的,相当于否定了二期的结果,这就增加了很
大的不确定性
after
t
【在 g****e 的大作中提到】
: 本想抽插一下,想不到成了股东。
: 话说一切都有可能,下10上20。其实它家的药到现在为止是最好的。只是不能提前上市
:
: “Prosensa and Glaxo started to lose ground against Sarepta in August, after
: the two companies released disappointing phase 2 trial results that didn't
: measure up to Sarepta's. One particular damaging comparison was in the
: production of dystrophin, a protein required for muscle growth that DMD
: patients lack. Prosensa's drug showed dystrophin production in 72% of
: patients receiving a continuous dose of the drug, whereas Sarepta's drug
: resulted in a 100% success rate. ”
原来的ENDPOINT可能不能用了,要改用新的,相当于否定了二期的结果,这就增加了很
大的不确定性
after
t
【在 g****e 的大作中提到】
: 本想抽插一下,想不到成了股东。
: 话说一切都有可能,下10上20。其实它家的药到现在为止是最好的。只是不能提前上市
:
: “Prosensa and Glaxo started to lose ground against Sarepta in August, after
: the two companies released disappointing phase 2 trial results that didn't
: measure up to Sarepta's. One particular damaging comparison was in the
: production of dystrophin, a protein required for muscle growth that DMD
: patients lack. Prosensa's drug showed dystrophin production in 72% of
: patients receiving a continuous dose of the drug, whereas Sarepta's drug
: resulted in a 100% success rate. ”
g*e
6 楼
龙老师对其股票有啥看法?以便参考。
f*1
8 楼
SRPT 今天的瀑布很壮观呀。36刀直接跌到13。8
难到今天就要到10?大牛说说啥时候能捞?
难到今天就要到10?大牛说说啥时候能捞?
f*1
10 楼
忍不住了, 14刀暴入1000股。
g*e
11 楼
Only hope is insider to buy. Only insider knows if the drug really works.
f*1
12 楼
靠, 亏废了, 飞刀真的不能瞎接。 俩小时 600刀没了。割肉吧。
b*p
13 楼
教训就是:鸟神有捞的,青蛙捞了也不定能赚;鸟神没有捞的,青蛙就一定不要捞。
相关阅读